These overall results implied that TRR has the ability to improve hyperglycemia possibly partly through insulin–pAkt–p-FOXO1 pathway or/and partly via AMPK activation to inhibit glucose production in liver tissues. The gene discussed is FOXO1; the disease is Hyperglycemia.